Adamantiades-Behcet disease: Diagnosis and current concepts in management of ocular manifestations

Comprehensive Ophthalmology Update

Volumn 8, Issue 4, 2007, Pages 225-233

  Durrani, Khayyam ^a   Ahmed, Muna ^b   Foster, C Stephen ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^c MASSACHUSETTS EYE RESEARCH AND SURGERY INSTITUTION   (United States)

Author keywords

Adamantiades Behcet disease; Diagnostic criteria; Immunomodulatory agents; Ocular signs

Indexed keywords

AZATHIOPRINE; CHLORAMBUCIL; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; INFLIXIMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; TRIAMCINOLONE ACETONIDE;

BEHCET DISEASE; BLINDNESS; CLINICAL FEATURE; DEATH; HUMAN; INFLAMMATION; PREVALENCE; RETINA DISEASE; REVIEW; SEX DIFFERENCE; TURKEY (REPUBLIC);

BEHCET SYNDROME; DIAGNOSIS, DIFFERENTIAL; FLUORESCEIN ANGIOGRAPHY; FUNDUS OCULI; HUMANS; IMMUNOLOGIC FACTORS; PROGNOSIS; RETINAL VASCULITIS; VISUAL ACUITY;

EID: 36749103727     PISSN: 15277313     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Devlin T, Gray L, Allen NB, et al: Neuro-Behçet's disease: factors hampering proper diagnosis. Neurology 45: 1754-7, 1995
2. Yurdakul S, Günaydin I, Tüzün Y, et al: The prevalence of Behçet's syndrome in a rural area in northern Turkey. J Rheumatol 15: 820-2, 1988
3. Yamamoto S, Toyokawa H, Matsubara J: A nation-wide survey of Behcet's disease in Japan: 1. Epidemiological survey. Jpn J Ophthalmol 18: 282-90, 1974
4. Chajek T, Fainaru M: Behçet's disease. Report of 41 cases and a review of the literature. Medicine (Baltimore) 54: 179-96, 1975
5. Foster CS, Baer JC, Raizman MB: Therapeutic responses to systemic immunosuppressive chemotherapy agents in patients with Behçet's syndrome affecting the eyes, in O'Duffy JD, Kokmen E (eds): Behçet's Disease: Basic and Clinical Aspects. New York, Informa Healthcare, 1991, pp 581-8
6. O'Duffy JD, Taswell HF, Elveback LR: HL-A antigens in Behcet's disease. J Rheumatol 3: 1-3, 1976
7. Yazici H, Chamberlain MA, Schreuder I, et al: HLA antigens in Behçet's disease: a reappraisal by a comparative study of Turkish and British patients. Ann Rheum Dis 39: 344-8, 1980
8. Behcet's Disease Research Committee of Japan: Behcet's disease: Guide to diagnosis of Behcet's disease. Jpn J Ophthalmol 18: 291-4, 1974
9. _: Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease. Lancet 335: 1078-80, 1990
10. Ferraz MB, Walter SD, Heymann R, et al: Sensitivity and specificity of different diagnostic criteria for Behçet's disease according to the latent class approach. Br J Rheumatol 34: 932-5, 1995
11. O'Neill TW, Rigby AS, Silman AJ, et al: Validation of the International Study Group criteria for Behçet's disease. Br J Rheumatol 33: 115-7, 1994
12. Kurumety U, Okada AA, Usui M, Rao NA: Behcet's syndrome, in Yanoff M, Duker JS (eds): Ophthalmology. London, Mosby, 1999, pp 1-4
13. Mishima S, Masuda K, Izawa Y, et al: The eighth Frederick H. Verhoeff Lecture. presented by saiichi mishima, MD Behçet's disease in Japan: ophthalmologic aspects. Trans Am Ophthalmol Soc 77: 225-79, 1979
14. Cohen S, Kremer I: Bilateral corneal immune ring opacity in Behçet's syndrome. Arch Ophthalmol 109: 324-5, 1991
15. Ehrlich GE: Vasculitis in Behçet's disease. Int Rev Immunol 14: 81-8, 1997
16. Evereklioglu C: Current concepts in the etiology and treatment of Behçet disease. Surv Ophthalmol 50: 297-350, 2005
17. Atmaca LS, BatioCrossed d signlu F, Idil A: Retinal and disc neovascularization in Behçet's disease and efficacy of laser photocoagulation. Graefes Arch Clin Exp Ophthalmol 234: 94-9, 1996
18. Atmaca LS: Fundus changes associated with Behçet's disease. Graefes Arch Clin Exp Ophthalmol 227: 340-4, 1989
19. Wolf SM, Schotland DL, Phillips LL: Involvement of nervous system in Behcet's syndrome. Arch Neurol 12: 315-25, 1965
20. James DG, Spiteri MA: Behçet's disease. Ophthalmology 89: 1279-84, 1982
21. Pamir MN, Kansu T, Erbengi A, et al: Papilledema in Behçet's syndrome. Arch Neurol 38: 643-5, 1981
22. Kansu T, Kadayifcilar S: Visual aspects of Behçet's disease. Curr Neurol Neurosci Rep 5: 382-8, 2005
23. Kural-Seyahi E, Fresko I, Seyahi N, et al: The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 82: 60-76, 2003
24. Elgin U, Berker N, Batman A: Incidence of secondary glaucoma in behcet disease. J Glaucoma 13: 441-4, 2004
25. Jabs DA, Rosenbaum JT, Foster CS, et al: Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 130: 492-513, 2000
26. Biswas J, Rao NA: Management of intraocular inflammation, in Ryan SJ (ed): Retina. St. Louis, Mosby-Year Book, 1994, vol 2, pp 1061-9
27. Mamo JG: The rate of visual loss in Behçet's disease. Arch Ophthalmol 84: 451-2, 1970
28. Benezra D, Cohen E: Treatment and visual prognosis in Behçet's disease. Br J Ophthalmol 70: 589-92, 1986
29. Toker E, KazokoCrossed d signlu H, Acar N: High dose intravenous steroid therapy for severe posterior segment uveitis in Behçet's disease. Br J Ophthalmol 86: 521-3, 2002
30. Santamaria J: Steroidal agents: The systemic and ocular complications. Ocul Inflamm Ther 1: 19-25, 1988
31. Karacorlu M, Mudun B, Ozdemir H, et al: Intravitreal triamcinolone acetonide for the treatment of cystoid macular edema secondary to Behcet disease. Am J Ophthalmol 138: 289-91, 2004
32. Ohguro N, Yamanaka E, Otori Y, et al: Repeated intravitreal triamcinolone injections in Behçet disease that is resistant to conventional therapy: one-year results. Am J Ophthalmol 141: 218-20, 2006
33. Mamo JG, Azzam SA: Treatment of Behçet's disease with chlorambucil. Arch Ophthalmol 84: 446-50, 1970
34. Pivetti Pezzi P, Gasparri V, De Liso P, et al: Prognosis in Behcet's disease. Ann Ophthalmol 17: 20-5, 1985
35. Tessler HH, Jennings T: High-dose short-term chlorambucil for intractable sympathetic ophthalmia and Behçet's disease. Br J Ophthalmol 74: 353-7, 1990
36. Tabbara KF: Chlorambucil in Behçet's disease. A reappraisal. Ophthalmology 90: 906-8, 1983
37. Blumenfeld Z, Haim N: Prevention of gonadal damage during cytotoxic therapy. Ann Med 29: 199-206, 1997
38. Yazici H, Pazarli H, Barnes CG, et al: A controlled trial of azathioprine in Behçet's syndrome. N Engl J Med 322: 281-5, 1990
39. Hijikata K, Masuda K: Visual prognosis in Behcet's disease: Effects of cyclophosphamide and colchicine. Jpn J Ophthalmol 22: 506-19, 1978
40. Oniki S, Kurakazu K, Kawata K: Immunosuppressive treatment of Behcet's disease with cyclophosphamide. Jpn J Ophthalmol 20: 32-40, 1976
41. Gills JP, Buckley CE: Cyclophosphamide therapy of Behcet's disease. Ann Ophthalmol 2: 399-405, 1970
42. Fain O, Du LTH, Wechsler B: Pulse cyclophosphamide in Behçet's disease, in O'Duffy JD, Kokmen E (eds): Behçet's Disease: Basic and Clinical Aspects. New York Informa Healthcare, 1991, pp 581-8
43. Ozyazgan Y, Yurdakul S, Yazici H, et al: Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet's syndrome: a single masked trial. Br J Ophthalmol 76: 241-3, 1992
44. de Smet MD, Nussenblatt RB: Clinical use of cyclosporine in ocular disease. Int Ophthalmol Clin 33: 31-45, 1993
45. Nussenblatt RB, Palestine AG, Chan CC, et al: Effectiveness of cyclosporin therapy for Behçet's disease. Arthritis Rheum 28: 671-9, 1985
46. Nussenblatt RB, Palestine AG, Rook AH, et al: Treatment of intraocular inflammatory disease with cyclosporin A. Lancet 2: 235-8, 1983
47. Nussenblatt RB, Palestine AG, Chan CC: Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Am J Ophthalmol 96: 275-82, 1983
48. Nussenblatt RB, Palestine AG, Chan CC: Cyclosporine therapy for uveitis: long-term followup. J Ocul Pharmacol 1: 369-82, 1985
49. Binder AI, Graham EM, Sanders MD, et al: Cyclosporin A in the treatment of severe Behçet's uveitis. Br J Rheumatol 26: 285-91, 1987
50. Whitcup SM, Salvo EC, Nussenblatt RB: Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behçet's disease. Am J Ophthalmol 118: 39-45, 1994
51. Sajjadi H, Soheilian M, Ahmadieh H, et al: Low dose cyclosporin-A therapy in Behçet's disease. J Ocul Pharmacol 10: 553-60, 1994
52. Atmaca LS, BatioCrossed d signlu F: The efficacy of cyclosporin-a in the treatment of Behçet's disease. Ophthalmic Surg 25: 321-7, 1994
53. Hayasaka S, Kawamoto K, Noda S, et al: Visual prognosis in patients with Behçet's disease receiving colchicine, systemic corticosteroid or cyclosporin. Ophthalmologica 208: 210-3, 1994
54. Chavis PS, Antonios SR, Tabbara KF: Cyclosporine effects on optic nerve and retinal vasculitis in Behçet's disease. Doc Ophthalmol 80: 133-42, 1992
55. Schreiber SL, Crabtree GR: The mechanism of action of cyclosporin A and FK506. Immunol Today 13: 136-42, 1992
56. Mochizuki M, Masuda K, Sakane T, et al: A clinical trial of FK506 in refractory uveitis. Am J Ophthalmol 115: 763-9, 1993
57. Jorizzo JL, Solomon AR, Zanolli MD, et al: Neutrophilic vascular reactions. J Am Acad Dermatol 19: 983-1005, 1988
58. Levy M, Spino M, Read SE: Colchicine: a state-of-the-art review. Pharmacotherapy 11: 196-211, 1991
59. Matsumura N, Mizushima Y: Leucocyte movement and colchicine treatment in Behcet's disease. Lancet 2: 813, 1975
60. Raynor A, Askari AD: Behçet's disease and treatment with colchicine. J Am Acad Dermatol 2: 396-400, 1980
61. Larkin G, Lightman S: Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease. Ophthalmology 106: 370-4, 1999
62. Sayinalp N, Ozcebe OI, Ozdemir O, et al: Cytokines in Behçet's disease. J Rheumatol 23: 321-2, 1996
63. Benitez-del-Castillo JM, Martinez-de-la-Casa JM, Pato-Cour E, et al: Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab). Eye 19: 841-5, 2005
64. Wechsler B, Sablé-Fourtassou R, Bodaghi B, et al: Infliximab in refractory uveitis due to Behçet's disease. Clin Exp Rheumatol 22(4 Suppl 34): S14-6, 2004
65. Giansanti F, Barbera ML, Virgili G, et al: Infliximab for the treatment of posterior uveitis with retinal neovascularization in Behçet disease. Eur J Ophthalmol 14: 445-8, 2004
66. Ohno S, Nakamura S, Hori S, et al: Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol 31: 1362-8, 2004
67. Saurenmann RK, Levin AV, Rose JB, et al: Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology (Oxford) 45: 982-9, 2006
68. Hale S, Lightman S: Anti-TNF therapies in the management of acute and chronic uveitis. Cytokine 33: 231-7, 2006
69. Sfikakis PP: Behçet's disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis 61 (Suppl 2): ii51-3, 2002
70. Wizemann AJ, Wizemann V: Therapeutic effects of short-term plasma exchange in endogenous uveitis. Am J Ophthalmol 97: 565-72, 1984
71. Yasui K, Ohta K, Kobayashi M, et al: Successful treatment of Behçet disease with pentoxifylline. Ann Intern Med 124: 891-3, 1996
72. Kötter I, Zierhut M, Eckstein AK, et al: Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol 87: 423-31, 2003
73. Rojas B, Zafirakis P, Foster CS: Cataract surgery in patients with uveitis. Curr Opin Ophthalmol 8: 6-12, 1997
74. Foster CS, Fong LP, Singh G: Cataract surgery and intraocular lens implantation in patients with uveitis. Ophthalmology 96: 281-8, 1989
75. Tabbara KF, Chavis PS: Cataract extraction in Behçet's disease. Ocul Immunol Inflamm 5: 27-32, 1997
76. Foster CS, Stavrou P, Zafirakis P, et al: Intraocular lens removal from [corrected] patients with uveitis. Am J Ophthalmol 128: 31-7, 1999
77. Alió JL, Chipont E, BenEzra D, et al: Comparative performance of intraocular lenses in eyes with cataract and uveitis. J Cataract Refract Surg 28: 2096-108, 2002
78. Androudi S, Ahmed M, Fiore T, et al: Combined pars plana vitrectomy and phacoemulsification to restore visual acuity in patients with chronic uveitis. J Cataract Refract Surg 31: 472-8, 2005
79. Tugal-Tutkun I, Havrlikova K, Power WJ, et al: Changing patterns in uveitis of childhood. Ophthalmology 103: 375-83, 1996
80. Diamond JG, Kaplan HJ: Lensectomy and vitrectomy for complicated cataract secondary to uveitis. Arch Ophthalmol 96: 1798-1804, 1978
81. Colvard DM, Robertson DM, O'Duffy JD: The ocular manifestations of Behćet's disease. Arch Ophthalmol 95: 1813-7, 1977
82. Diri E, Espinoza LR: Neuro-Behçet's syndrome: differential diagnosis and management. Curr Rheumatol Rep 8: 317-22, 2006